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Abstract
Introduction: Mild therapeutic hypothermia (MTH) is a worldwide used therapy to improve neurological outcome
in patients successfully resuscitated after cardiac arrest (CA). Preclinical data suggest that timing and speed of
induction are related to reduction of secondary brain damage and improved outcome.
Methods: Aiming at a rapid induction and stable maintenance phase, MTH induced via continuous peritoneal
lavage (PL) using the Velomedix® Inc. automated PL system was evaluated and compared to historical controls in
which hypothermia was achieved using cooled saline intravenous infusions and cooled blankets.
Results: In 16 PL patients, time to reach the core target temperature of 32.5°C was 30 minutes (interquartile range
(IQR): 19 to 60), which was significantly faster compare to 150 minutes (IQR: 112 to 240) in controls. The median
rate of cooling during the induction phase in the PL group of 4.1°C/h (IQR: 2.2 to 8.2) was significantly faster
compared to 0.9°C/h (IQR: 0.5 to 1.3) in controls. During the 24-hour maintenance phase mean core temperature in
the PL patients was 32.38 ± 0.18°C (range: 32.03 to 32.69°C) and in control patients 32.46 ± 0.48°C (range: 31.20 to
33.63°C), indicating more steady temperature control in the PL group compared to controls. Furthermore, the
coefficient of variation (VC) for temperature during the maintenance phase was lower in the PL group (VC: 0.5%)
compared to the control group (VC: 1.5%). In contrast to 23% of the control patients, none of the PL patients
showed an overshoot of hypothermia below 31°C during the maintenance phase. Survival and neurological
outcome was not different between the two groups. Neither shivering nor complications related to insertion or
use of the PL method were observed.
Conclusions: Using PL in post-CA patients results in a rapidly reached target temperature and a very precise
maintenance, unprecedented in clinical studies evaluating MTH techniques. This opens the way to investigate the
effects on neurological outcome and survival of ultra-rapid cooling compared to standard cooling in controlled
trials in various patient groups.
Trial Registration: ClinicalTrials.gov: NCT01016236
Introduction
Most patients who suffer a cardiac arrest (CA) do not
survive, and full neurological recovery occurs in only 6
to 23% [1]. Mild therapeutic hypothermia (MTH) is
nowadays an established treatment to limit neurological
injury and to improve outcome in CA patients after suc-
cessful resuscitation [2,3]. Based on two prospective
clinical trials [2,3], the International Liaison Committee
on Resuscitation has recommended that all unconscious
adult patients with spontaneous circulation after out-of-
hospital CA as a result of ventricular fibrillation should
be cooled to 32 to 34°C for 12 to 24 hours [4]. Many
techniques for inducing and maintaining hypothermia
and for controlled re-warming have been described
[5-7]. However, the rate of lowering body temperature
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to achieve target temperature and the stability of target
temperature during the maintenance phase still need to
be optimized [3,4,8,9]. The clinical benefits of interven-
ing in the process of ischemic and reperfusion injury
using MTH are thought to be greatest when achieved as
early and as fast as possible. Although pre-clinical ani-
mal studies have shown beneficial effects of starting
prior to or during early reperfusion with therapeutic
hypothermia [10-12], translation of the approach of
early cooling to humans is still difficult. Interestingly,
Bernard et al. [8] found that a fast cooling rate of 1.6°C/h
using rapid intravenous infusion of cold lactated Ringers
solution, in 22 comatose patients following resuscitation
from CA, was safe and effective. Compared to historical
controls, outcome was significantly improved with no
increase in complications. Howes et al. [13] achieved
rapid induction of therapeutic hypothermia with a cool-
ing rate of 3.0°C/h using convective-immersion surface
cooling resulting in an excellent survival rate. In contrast,
a faster decline in body temperature to 34°C appears to
predict an unfavourable neurological outcome in a study
by Haugk et al. [14]. Although (pre-) clinical studies
strongly suggest that timing and speed of induction of
MTH are related to reduction of secondary brain damage
and improved outcome, translation to improved clinical
care has not yet been established.
As part of a multi-center trial, we tested a new appli-
cation of MTH rapidly induced via peritoneal lavage.
The equipment used is a modification of existing tech-
nologies and standard techniques which are used on a
daily basis in peritoneal dialysis and laparoscopic surgery
[15]. The system is designed to induce, maintain and
reverse MTH by continuous lavage of the peritoneal
cavity with lactated Ringers solution. This article reports
preliminary results on the safety and feasibility of indu-
cing MTH using peritoneal lavage compared with con-
ventional cold, intravenous infusion and cooling
blankets.
Materials and methods
Patients in the peritoneal lavage group
As part of a multi-center prospective observational
study, we tested a new application to induce MTH
using the Velomedix® Inc. automated peritoneal lavage
(PL) system (San Francisco, CA, USA). The Velomedix
automated PL system is an investigational device from
the United States, limited by Federal (United States) law
to investigational use. In our institute (VU University
Medical Center, Amsterdam, The Netherlands), 16
unconscious, mechanically ventilated patients with
return of spontaneous circulation (ROSC) after CA
requiring standard treatment with MTH were admitted
to the ICU between November 2010 and July 2011,
and included in the PL group. The research ethics
committee of the VU University Medical Center, Amster-
dam, The Netherlands, approved the study protocol and
consent procedures. All patients provided written
informed consent.
We excluded patients less than 18 years of age, with a
core temperature of less than 34°C upon presentation
after ROSC, a history of abdominal surgery, peritonitis
or currently undergoing peritoneal dialysis, active
uncontrolled bleeding or coagulopathy, a known history
of receiving thrombolytic medication in the previous six
weeks (treatment with other anticoagulant medications,
such as those required for percutaneous coronary inter-
vention (PCI) or ST-segment Elevation Myocardial
Infarction (STEMI) treatment, is not an exclusion),
known significant concomitant illness with a life expec-
tancy of less than one year, known enrollment in another
study, or pregnant patients. Figure 1 shows patients
screened for enrollment included or excluded for the PL
hypothermia group in a flow diagram. Excluded patients
received non-invasive MTH as part of the standard care
for these patients.
Sedation was maintained using intravenous adminis-
tration of propofol and fentanyl, and shivering was trea-
ted with fentanyl boluses when necessary, according to
standard institutional procedure for post-resuscitative
therapeutic hypothermia. An EndoTIP peritoneal access
port (Karl Storz, Tuttlingen, Germany), commercially
available for routine laparoscopic surgery access, was
used for blunt (non-cutting) lateral dissection of abdom-
inal wall tissue. The EndoTIP was used in combination
with the Peritoneal Entry Indicator ((PEI), Karl Storz,
Tuttlingen, Germany), a proprietary fluid reservoir that
attaches to the proximal end of the EndoTIP. Entry into
the peritoneal cavity was detected by observing the
Screened 
Included Excluded 
Alive 
Dead 
Alive 
Dead 
64 
16 (25%) 48 (75%) 
5 (31%) 24 (50%) 
11 (69%) 24 (50%) 
Figure 1 Flow diagram showing patients screened for
enrollment, included/excluded for the peritoneal lavage
hypothermia group. Excluded patients received non-invasively
MTH as part of the standard care for these patients. Mortality and
survival rates at ICU discharge are incorporated in the flow diagram.
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rapid drop of fluid from the PEI into the peritoneal cav-
ity. Once entry was detected, the PEI was removed and
a disposable peritoneal catheter was placed through the
lumen of the access port. The access port was removed
and the catheter was connected to the Velomedix® sys-
tem. The disposable peritoneal lavage catheter is a mul-
tiple lumen device made from a dual lumen extrusion
for fluid transfer with a floating third lumen for cavity
pressure measurement. During hypothermic treatment,
lactated Ringer’s irrigation solution (Baxter, Deerfield,
Illinois, USA) was continuously infused and extracted
through independent lumens in the catheter. An eso-
phageal temperature probe was inserted for continuous
temperature monitoring and connected to the system to
monitor the subject’s temperature during the whole
treatment. When a target temperature of 32.5°C was
reached, the induction phase was automatically followed
by maintenance of hypothermia for 24 hours. Once the
maintenance hypothermic treatment time had elapsed,
the subject was automatically, gradually warmed to nor-
mothermic temperature at a predetermined rate of 0.5°
C/h. After the subject’s body temperature had returned
to 36°C the peritoneal cavity was drained automatically
by the system, the catheter was removed and the
abdominal entry incision was sutured by the physician.
Patients in the control group
Prospectively collected data from historical post-CA
patients with ROSC admitted to the ICU between July
2008 and August 2010 and eligible for MTH served as
controls. The control group consisted of 99 patients
who were treated with our standard method of MTH
using cooled saline intravenous infusion and cooled
blankets (Cincinnati Sub-Zero Medical, Cincinnati, OH,
USA) at the VU University Medical Center, Amsterdam,
The Netherlands. In the control group, MTH was part
of standard care; therefore, informed consent for this
group was waived. After admission to the ICU, the
patients were covered with cooling blankets and cooling
was started. An esophageal temperature probe was
inserted for continuous temperature monitoring. The
induction phase, carried out until a target temperature of
32.5°C was reached, was followed by the maintenance
phase of 24 hours at a temperature of 32.5°C, after which
controlled re-warming to 36°C was started.
Data collection
Prior to and during MTH treatment, details of the CA,
initial vital signs (including core temperature), baseline
ECG, initial lab work and temperatures were recorded
in our patient data monitoring system for critical care
(Metavision, iMDsoft®, Tel Aviv, Israel). Core body tem-
perature was recorded continuously during induction,
maintenance and the re-warming period of the MTH
protocol. Maximum temperature variability during the
maintenance period was calculated as the difference
between the maximum and minimal temperature during
24-hour maintenance. The mean coefficient of variation
(VC) for temperature during the maintenance phase was
calculated. The Glasgow Coma Scale (GCS) for each
patient still alive at the time of hospital discharge was
determined. Data on adverse effects, including shivering,
mortality, pneumonia, sepsis, significant arrhythmia,
renal failure, peritonitis and significant bleeding, within
seven days of the procedure were collected through ret-
rospective chart view.
Statistical analysis
We report continuous variables, which were not generally
normally distributed, as medians with 25% to 75% inter-
quartile ranges (IQR). Categorical variables are reported as
counts and percentages. To test for significant differences
between the two groups, we used the Mann-Whitney
U test for continuous variables and the chi-squared test
for categorical variables. A two-sided P ≤0.05 was consid-
ered to indicate statistical significance.
Results
A total of 16 comatose patients successfully resuscitated
from CA received MTH via PL. The PL group was com-
pared to a control group consisting of 99 post-CA patients
treated according to our standard MTH protocol. Table 1
shows the characteristics and outcome of the patients
enrolled, while Table 2 shows the cooling time and speed,
Table 1 Patient characteristics and outcome
Control
group
(n = 99)
PL group
(n = 16)
P-value
Gender, m/f 76/23 (77/23) 14/2 (87/13) 0.65
Age (years) 65 (57 to 73) 62 (57 to 69) 0.47
BMI (kg/m2) 25.4 (23.9
to 28.4)
26.6 (24.8
to 30.5)
0.19
OHCA 76 (77) 14 (88) 0.74
Witnessed arrest 63 (64) 11 (69) 0.86
Presenting rhythm VF/VT 43 (43) 10 (77) 0.49
CAG 36 (36) 10 (77) 0.24
PCI 21 (21) 6 (38) 0.37
Length of stay at ICU (h) 119 (75
to 231)
119 (77
to 164)
0.42
Mechanical ventilation (days) 4.0 (3.0 to 7.5) 5.0 (4.0 to 9.5) 0.38
Survival at ICU 46 (46) 11 (69) 0.38
Neuro-outcome at discharge
(GCS)
14.0 (10.0 to
15.0)
15.0 (13.5 to
15.0)
0.13
Continuous variables are median (interquartile range) and categorical
variables are absolute counts in numbers (percentages). BMI, body mass
index; CAG, Coronary angiogram; GCS, Glasgow Coma Scale; OHCA, out of
hospital cardiac arrest; PCI, Percutaneous coronary intervention; PL, peritoneal
lavage; VF, ventricular fibrillation; VT, ventricular tachycardia
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and temperature data. All patient characteristics and the
outcome parameters, length of stay at ICU, days on
mechanical ventilation, survival at ICU and neurological
outcome at discharge were comparable between the PL
and control group (Table 1).
Initial body temperatures were similar between both
groups (Table 2). Two out of 16 PL patients were
excluded from analysis of temperature parameters
because of malfunction of the equipment during the
beginning of the maintenance phase. Cooling was
initiated after admittance to the ICU. Patients in the PL
group reached core target temperatures of 32.5°C signif-
icantly faster compared to controls; 30 (IQR: 19 to 60)
versus 150 (IQR: 112 to 240) minutes, respectively. A
median cooling rate of 4.1°C/h (IQR: 2.2 to 8.2) in the
PL group was significantly faster compared to 0.9°C/h
(IQR: 0.5 to 1.3) in control patients. In the PL group,
cooling started within 169 minutes (IQR: 137 to 187)
after arrival at the hospital, which is significantly longer
compared to the control group. During the 24-hour
maintenance phase mean core temperatures were not
different between the groups (Table 2 and Figure 2).
However, the largest difference between the minimum
and maximum temperature during the 24-hour mainte-
nance phase was significantly less in the PL group (0.45°
C with IQR: 0.38 to 0.70) compared to the control
group (2.20°C with IQR: 1.70 to 3.05, Table 2 and Figure
2). Also, the coefficient of variation (VC) for tempera-
ture during the maintenance phase was lower in the PL
group (VC: 0.5%) compared to the control group (VC:
1.5%). None of the patients in the PL group showed an
overshoot of hypothermia below 31°C. However, 23% of
the control patients displayed core temperatures below
31°C during maintenance, indicating a more steady
maintenance phase in the PL group compared to the
controls. The re-warming phase in control patients was
significantly longer compared to PL patients (15.7 versus
12.8 hours, respectively).
In the PL group, no adverse events or complications
related to insertion of the catheter were observed.
Device-related skin complications, shivering during
MTH, bleeding, peritonitis, pneumonia, sepsis or the
need for hemodialysis in the period after MTH was not
different between the control and PL group (Table 3).
No significant difference was observed in serum creati-
nine levels between the control and PL groups during
the induction, maintenance or re-warming phases of
MTH (Table 4). Hematology parameters (Table 4)
showed that leukocyte, thrombocyte, PT and aPTT
serum levels were not different between the control and
PL groups throughout the MTH treatment. In both con-
trol and PL groups, leukocyte levels were lower during
the maintenance phase and both leukocyte and throm-
bocyte levels were lower during the re-warming phase
compared to the induction phase. Hemoglobin and
hematocrit levels were higher in the PL group compared
to the control group during the induction phase,
unchanged during maintenance and decreased only dur-
ing re-warming in the PL group. Also, aPTT decreased
in the PL group during the re-warming compared to the
induction phase. Gastro-intestinal problems or massive
inflammatory reaction were not observed in any of the
PL patients. However, note that the number of enrolled
patients is probably too low to detect complications
related to prolonged cooling of the gut.
Discussion
The present study investigated for the first time the
safety and feasibility of rapid induction of MTH via
peritoneal lavage using the Velomedix® automated PL
system in CA patients after successful resuscitation. We
demonstrate that PL is an ultra-rapid and safe cooling
Table 2 Mild therapeutic hypothermia timing and temperature data
Control group PL group P-value
First temperature measured (°C) 35.0 (34.0 to 35.6) 35.0 (34.9 to 35.7) 0.14
Induction:
Start time (min) 74 (52 to 130) 169 (137 to 187)* 0.0001
Time to target temperature of 32.5°C (min) 150 (112 to 240) 30 (19 to 60)* <0.0001
Cooling rate (°C/h) 0.9 (0.5 to 1.3) 4.1 (2.2 to 8.2)* 0.01
Maintenance:
Mean temperature (°C) 32.4 (32.1 to 32.8) 32.4 (32.4 to 32.5) 0.28
Lowest temperature (°C) 31.2 (31.0 to 31.7) 32.2 (32.2 to 32.3)* <0.0001
Temperature <31°C, n (%) 23 (23) 0 (0) 0.066
Temperature variability (°C) 0.45 (0.38 to 0.70) 2.20 (1.70 to 3.05)* <0.0001
Re-warming:
Duration to reach 36.5°C (h) 15.7 (11.0 to 23.0) 12.8 (10.0 to 14.8)* 0.005
Continuous variables are median (interquartile range) and categorical variables are counts (percentages). PL, peritoneal lavage. *P ≤0.05 Lavage versus Control
group.
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technique for reaching and maintaining post-CA
patients at a target temperature of 32.5°C for a period of
24 hours. The main findings were as follows: (i) PL
resulted in a significantly faster time to reach core target
temperatures of 32.5°C; (ii) patients in the PL group
showed less variation in temperature during the 24-hour
maintenance phase; and (iii) the PL group had a signifi-
cantly shorter and more controlled re-warming phase
compared to control patients who were cooled with saline
intravenous infusion and cooled blankets. Furthermore, in
our cohort no serious complications related to the therapy
and procedure were observed.
Figure 2 Temperature control during 24-hour maintenance phase of therapeutic hypothermia. (A) Maximum, minimum and mean
temperature during the 24 hour maintenance phase of PL and control groups. Data are mean ± SD. White bars are controls and black bars are
PL (Lavage) groups. *P < 0.05 PL versus control group. (B) Temperature variability, calculated as difference between maximum and minimum
temperature per patient, during the 24-hour maintenance phase in control and PL patients. *P < 0.05 PL group versus control group.
Table 3 Complication rates
Clinical condition Control group
(n = 99)
PL group
(n = 16)
Device related skin complications 3 (3%) 0 (0%)
Shivering (one or more episodes) 2 (2%) 1 (6%)
Bleeding requiring transfusion 4 (4%) 1 (6%)
Peritonitis 0 (0%) 0 (0%)
Pneumonia 4 (4%) 1 (6%)
Sepsis 7 (7%) 1 (6%)
Acute renal failure requiring hemodialysis 14 (14%) 3 (19%)
All values are No. of patients and (%).
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Over the past decade several randomized- and histori-
cal-controlled trials have shown beneficial effects of
MTH on neurological outcome and survival in patients
after CA [2,3,16-19]. However, these trials have not yet
shown clear evidence for the optimal timing of initiating
MTH, rate of cooling and time to reach the target tem-
perature after CA. So far, the benefits of early or rapid
cooling have only been demonstrated in animal models
testing the effects of brief periods of therapeutic
hypothermia. These studies showed that even a minor
temperature decrease before, during or immediately
after the time of cardiac arrest was associated with ben-
efits in neurological outcome [10,20-22]. Although no
prospective randomized clinical trials have assessed the
effect of time to reach target temperature on neurologi-
cal outcome, there are signs that support a benefit to
rapid cooling. Wolff et al. [23] studied rapidly cooled
patients, using an endovascular device, and showed that
the time to target temperature was an independent pre-
dictor of good outcome. Although underpowered, recent
clinical trials of rapid cooling devices have shown trends
towards survival benefit [24] and improvement in
patient outcomes compared to historical controls [13].
Kory et al. [25] published a fast cooling method, using a
combination of core and surface cooling modalities
without the use of a commercial device, which resulted
in a cooling rate of 2.6°C/h. Moreover, cooling via gas-
tric lavage is a technique used to achieve rapid cooling
of hyperthermic patients [26]. Unfortunately, none of
these cooling methods seem to be superior in generating
an ultra-rapid cooling speed. Merchant et al. [27] have
expressed concern that temperature overshoot below 32°
C may be associated with adverse hemodynamic and
arrhythmic effects. In our study we showed that in con-
trast to 24% of the control patients, none of the patients
in the PL group reached temperatures below 31°C.
Recently, Haugk et al. [14] reported a retrospective
analysis of 13 years of therapeutic hypothermia patients,
suggesting a surprising association between faster cool-
ing rates and less favourable neurological outcomes. The
authors suggested that their findings might well imply
that greater neurological injury is predicted by more
rapid achievement of cooling during therapeutic
hypothermia, rather than rapid cooling itself being
inherently harmful. In patients with poor neurological
outcomes, the initial temperatures were significantly
lower before therapeutic hypothermia was started, sug-
gesting that these patients already show some degree of
impaired thermoregulation. Alternatively, it appears that
sicker patients lack homeostatic mechanisms to main-
tain normothermia and, therefore, cool faster. In our
study, temperatures at the start of cooling were not dif-
ferent between the two groups. The five-times faster
cooling rate in the PL group (4.7°C/h) compared to the
control group (0.9°C/h) can, therefore, not be attributed
to impaired thermoregulation.
Limitations
This study, reporting on the first experience with a new
technique at a single institution, is a controlled trial, but
with the use of historical controls. Selection bias is pre-
sent in this study due to the exclusion of patients with a
history of abdominal surgery and the inclusion of a rela-
tively small number of patients. Therefore, our results of
ultra-fast cooling via PL may not be translated directly
to other hospitals.
Also, the time interval from hospitalization to target
temperature is mainly dependent upon team organiza-
tion and the technique used to induce MTH. On aver-
age, it took 168 minutes after hospitalization to start
with the cooling therapy and after cooling was started
only 30 minutes to achieve the target temperature in the
PL group. The time to initiation of cooling was longer
in the PL group compared to the control group, but tar-
get temperature was reached much faster than in the
controls. This can be explained by the period needed to
Table 4 Laboratory values
Induction phase Maintenance phase Re-warming phase
Control group PL group Control group PL group Control group PL group
Hematology
Leucocytes (109/l) 15 (12 to 19) 14 (11 to 16) 12 (9 to 15)† 10 (9 to 13)† 10 (8 to 13)† 9 (8 to 11)†
Thrombocytes (109/l) 207 (168 to 249) 259 (217 to 288) 192 (155 to 227) 197 (183 to 248) 149 (116 to 205)† 167 (152 to 196)†
Hemoglobin (mmol/l) 7.5 (6.5 to 8.6) 8.7 (8.3 to 9.2)* 7.4 (6.5 to 8.5) 8.2 (7.5 to 8.8) 7.1 (6.3 to 7.8) 7.7 (6.8 to 8.3)†
Hematocrit 0.35 (0.31 to 0.42) 0.40 (0.39 to 0.44)* 0.36 (0.31 to 0.41) 0.37 (0.35 to 0.40) 0.35 (0.31 to 0.38) 0.34 (0.33 to 0.38)†
PT (sec) 1.32 (1.19 to 1.57) 1.23 (1.20 to 1.51) 1.30 (1.20 to 1.52) 1.16 (1.15 to 1.28) 1.34 (1.22 to 1.54) 1.25 (1.21 to 1.60)
aPTT (sec) 74 (43 to 164) 107 (79 to 240) 83 (50 to 111) 87 (50 to 109) 68 (55 to 86) 76 (69 to 89)†
Renal function
Serum creatinine (μmol/l) 96 (78 to 125) 96 (89 to 99) 89 (62 to 134) 92 (79 to 105) 100 (65 to 155) 113 (78 to 151)
Continuous values are presented as median (interquartile range). Parameters are presented as average for each therapeutic hypothermia phase. * P < 0.05 versus
corresponding control group, † P < 0.05 versus corresponding group in induction phase.
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obtain informed consent from a legal representative,
which is necessary for the PL patients. Secondly, inser-
tion of the PL catheter by a physician is at present
somewhat longer then applying cooled intravenous infu-
sion and blankets on the patient as used in the control
group. Apparently, there is still a great potential to
further optimize the period between hospitalization and
the start of cooling and thereby speed up the whole PL
procedure. One might initiate PL in the emergency
room, requiring, however, reorganization and in depth-
training of the cardiopulmonary resuscitation team. In
this study, we decided to test this new technique in a
controlled setting in the ICU. When this technique is
applied as a routine technique in the future, the timing
delay to start cooling will not be an issue. Finally, some
bias could have occurred in the patient population of
the PL group due to strict exclusion criteria. However,
patient characteristics were equal between control and
PL patients.
Applications
So far, only animal studies have shown benefits of faster
cooling rates; translation to clinical care has not yet
proved these benefits. Nowadays, one of the greatest
challenges is the introduction of rapid cooling methods
achieved in laboratory animals to human subjects, with
the hopes of observing similar therapeutic benefits. The
results of the present clinical study showed that PL
resulted in an extremely fast cooling rate and steady
maintenance phase during MTH therapy. These obser-
vations provide a unique opportunity to investigate the
effects of ultra-rapid cooling on neurological outcome
and survival in prospective controlled trials in various
patient groups; such as its use in emergent situations,
where there is a possible benefit of inducing MTH prior
to adjunct therapy, or in the case of percutaneous cor-
onary revascularization to reduce infarct size following
acute myocardial infarction. Furthermore, another group
of patients who can benefit from ultra-rapid cooling are
patients with acute neurological injuries, such as stroke.
Conclusions
This study shows the first experience with a novel tech-
nique for induction of MTH. In a short period of time a
substantial number of patients were included, which
demonstrates the feasibility of this novel technique. The
results demonstrate evidence for an extremely rapid,
safe and feasible way of applying MTH via peritoneal
lavage in a controlled ICU tting compared to historical
controls. Whether this also holds in the emergency
room or in a cardiology environment, during the acute
post-cardiopulmonary resuscitation phase, remains to be
determined.
Key messages
• Peritoneal lavage is an ultra-rapid technique to
achieve mild therapeutic hypothermia in patients
with ROSC after CA.
• Peritoneal lavage shows a very stable temperature
control during the 24-hour maintenance phase of
MTH.
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